Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France
Publication: Diabetes Technology & Therapeutics
Volume 18, Issue Number 2
Abstract
Background: Sensor-augmented pump therapy (SAP) provides a useful adjunct relative to continuous subcutaneous insulin infusion (CSII) alone. It can provide early warning of the onset of hyperglycemia and hypoglycemia and has the functionality to suspend insulin delivery if sensor glucose levels fall below a predefined threshold. The aim was to assess the cost-effectiveness of SAP with low glucose suspend (LGS) versus CSII alone in type 1 diabetes.
Materials and Methods: Cost-effectiveness analysis was performed using the CORE Diabetes Model, using published clinical input data. The analysis was performed in two cohorts: one with uncontrolled glycated hemoglobin at baseline and one at elevated risk for hypoglycemic events. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon; future costs and clinical outcomes were discounted at 4% per annum.
Results: In patients with uncontrolled glycated hemoglobin at baseline, SAP + LGS resulted in improved discounted quality-adjusted life expectancy (QALE) versus CSII (10.55 quality-adjusted life-years [QALYs] vs. 9.36 QALYs) but higher mean lifetime direct costs (€84,972 vs. €49,171) resulting in an incremental cost-effectiveness ratio (ICER) of €30,163 per QALY gained. In patients at elevated risk for hypoglycemia, the ICER was €22,005 per QALY gained for SAP + LGS versus CSII as lifetime costs were higher (€88,680 vs. €57,097), but QALE was also higher (18.46 QALYs vs. 18.30 QALYs).
Conclusions: In France, projected improvements in outcomes with SAP + LGS versus CSII translated into an ICER generally considered as good value for money, particularly in patients who experience frequent and/or problematic hypoglycemic events.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
International Diabetes Federation: Diabetes Atlas Sixth Edition. 2013. www.idf.org/diabetesatlas/data-downloads (accessed September 3, 2014).
2.
Fagot-Campagna A, Romon I, Fosse S, et al.: Prévalence et Incidence du Diabète, et Mortalité Liée au Diabète en France. 2010. www.invs.sante.fr/publications/2010/plaquette_diabete/plaquette_diabete.pdf (accessed September 3, 2014).
3.
Chevreul K, Berg Brigham K, Bouché C: The burden and treatment of diabetes in France. Global Health 2014;10:6.
4.
Rapport d'Activité 2013 du Comité Économique des Produits de Santé. 2014;15:39–41. www.sante.gouv.fr/IMG/pdf/Rapport_d_activite_du_CEPS_en_2013_version_francaise_.pdf (accessed November 16, 2015).
5.
Lassmann-Vague V, Clavel S, Guerci B, et al.: When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabetes Metab 2010;36:79–85.
6.
Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774.
7.
Bergenstal RM, Klonoff DC, Garg SK, et al.: Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–232.
8.
Ly TT, Nicholas JA, Retterath A, et al.: Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240–1247.
9.
Riveline JP, Schaepelynck P, Chaillous L, et al.: Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care 2012;35:965–971.
10.
Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.
11.
Battelino T, Conget I, Olsen B, et al.: The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155–3162.
12.
O'Connell MA, Donath S, O'Neal DN, et al.: Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52:1250–1257.
13.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, et al.: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378–1383.
14.
Raccah D, Sulmont V, Reznik Y, et al.: Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:2245–2250.
15.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al.: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476.
16.
Hirsch IB, Abelseth J, Bode BW, et al.: Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008;10:377–383.
17.
Deiss D, Bolinder J, Riveline JP, et al.: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730–2732.
18.
Pickup JC, Freeman SC, Sutton AJ: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343.
19.
Lynch P, Attvall S, Persson S, Barsoe C, Gerdtham U. Routine use of personal continuous glucose monitoring system with insulin pump in Sweden [abstract 1052]. Diabetologia 2012;55(Suppl 1):S432.
20.
Palmer AJ, Roze S, Valentine WJ, et al.: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5–S26.
21.
Palmer AJ, Roze S, Valentine WJ, et al.: Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27–S40.
22.
McEwan P, Foos V, Palmer JL, et al.: Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714–724.
23.
Lafuma A, Colin X, Solesse A: Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. Arch Cardiovasc Dis 2008;101:327–332.
24.
Fagnani F, Souchet T, Labed D: Incidence, management and cost of cardio-vascular and renal complications in French type 2 diabetic patients in 2001. Value Health 2002;5:206.
25.
LePen C, Lilliu H, Keller T, et al.: The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998;14:49–58.
26.
Chevreul K, Durand-Zaleski I, Gouépo A, et al.: Cost of stroke in France. Eur J Neurol 2013;20:1094–1100.
27.
Blotière PO, Tuppin P, Weill A, et al.: The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation [in French]. Nephrol Ther 2010;6:240–247.
28.
Grueger J, O'Brien B, Caro J, et al.: The lifetime direct medical costs of managing diabetes and its complications in France [abstract]. Value Health 2001;4:504–505.
29.
Torreton E, Vandebrouck T, Emiel P, et al.: Cost of inpatient management of hypoglycemia in France [abstract]. Value Health 2013;16:A436.
30.
Bonastre J, Le Pen C, Soubrane G, et al.: The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181–190.
31.
Nghiem-Buffet MH, de Pouvourville G, Renard G, et al.: Cost of managing cataracts. Evaluation of traditional hospitalization and ambulatory surgery. Presse Med 2001;30:1924–1926.
32.
Palmer AJ, Sendi PP, Roze S, et al.: Comparaison du rapport coût-efficacité du contrôle strict de la glycémie par la metformine ou par une stratégie conventionnelle dans le système de soin français chez des diabétiques de type 2 présentant une surcharge pondérale. J Econ Med 2002;1:45–48.
33.
Agence Technique de l'Information sur l'Hospitalisation: Coûts Hospitaliers. www.atih.sante.fr/ (accessed June 1, 2013).
34.
Ghatnekar O, Persson U, Willis M, et al.: Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767–778.
35.
Institut National de la Statistique et des Études Économiques: Indice des Prix à la Consommation (Mensuel, Ensemble des Ménages, Métropole + DOM, Base 1998)—Nomenclature COICOP: 06.—Santé. www.insee.fr/fr/bases-de-donnees/bsweb/serie.asp?idbank=000637733 (accessed September 3, 2014).
36.
Institut National de la Statistique et des Études Économiques: Écart de Salaires Mensuels Nets Entre les Hommes et les Femmes en 2012. www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATTEF04154 (accessed August 26, 2014).
37.
Institut National de la Statistique et des Études Économiques: Durée de Travail des Personnes Travaillant à Temps Complet in 2012. www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATnon03259 (accessed August 26, 2014).
38.
Securite-Sociale.fr: Durée Moyenne de Vie au Travail. www.securite-sociale.fr/IMG/pdf/indicateur3-2_pqe_retraite.pdf (accessed August 26, 2014).
39.
Secuite-Sociale.fr: Age Effectif Moyen à la Cessation d'Activité. www.securite-sociale.fr/IMG/pdf/2011_plfss_pqe_retraite_4_2.pdf (accessed August 26, 2014).
40.
Beaudet A, Clegg J, Thuresson PO, et al.: Review of utility values for economic modeling in type 2 diabetes. Value Health 2014;17:462–470.
41.
Harris S, Mamdani M, Galbo-Jørgensen CB, et al.: The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes 2014;38:45–52.
42.
Nørgaard K, Scaramuzza A, Bratina N, et al.: Sensor-augmented pump therapy in real-life: patients reported outcomes results of the INTERPRET observational study [abstract 1058]. Presented at the European Association for the Study of Diabetes Meeting, Berlin, October 1–5, 2012.
43.
Nørgaard K, Scaramuzza A, Bratina N, et al.: Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther 2013;15:273–280.
44.
Currie CJ, Morgan CL, Poole CD, et al.: Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–1534.
45.
McBride M, Eggleston AS, Jones T, et al.: Health-related quality of life in patients with type 1 diabetes and impaired hypoglycaemia awareness: the role of sensor-augmented insulin pump therapy with automated insulin suspension [abstract]. Value Health 2013;16:A448.
46.
Haute Autorité de Santé: Choix Méthodologique pour l'Évaluation Économique à la HAS, Octobre 2011. www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf (accessed September 3, 2014).
47.
Yeh HC, Brown TT, Maruthur N, et al.: Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336–347.
48.
Benhamou PY, Catargi B, Delenne B, et al.: Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: consensus of experts from SFD, EVADIAC and SFE. Diabetes Metab 2012;38(Suppl 4):S67–S83.
49.
Hepburn DA, Patrick AW, Eadington DW, et al.: Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 1990;7:711–717.
50.
Geddes J, Wright RJ, Zammitt NN, et al.: An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care 2007;30:1868–1870.
51.
Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697–703.
52.
Brod M, Christensen T, Thomsen TL, et al.: The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665–671.
53.
Anderbro T, Amsberg S, Adamson U, et al.: Fear of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2010;27:1151–1158.
54.
Ly TT, Brnabic AJ, Eggleston A, et al.: A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014;17:561–569.
Information & Authors
Information
Published In
Diabetes Technology & Therapeutics
Volume 18 • Issue Number 2 • February 2016
Pages: 75 - 84
PubMed: 26646072
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published online: 3 February 2016
Published in print: February 2016
Published ahead of print: 8 December 2015
Topics
Authors
Author Disclosure Statement
M.C. and H.H. have received consulting fees from Medtronic. J.S.-P. and W.V. are current employees of Ossian Health Economics and Communications, which has received consulting fees from Medtronic International Sàrl. S.R. is a current employee of HEVA HEOR, which has received consulting fees from Medtronic International Sàrl. S.P. and N.P are current employees of Medtronic International Trading Sàrl. V.P. is a current employee of Medtronic France SAS.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.